Lock Members Only close arrow-right cart search google-plus facebook twitter youtube flickr linkedin calendar user menu menu-close print share circle-down help briefcase latest recon star word-bubble news
RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.
Skip to Main Navigation Skip to Main Content Skip to Footer
8553b334-65f3-4a6c-bf5b-1d8fd1551c9a
Close Login

Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.

E-mail address & Password Combo is invalid
  • Forgot Password?
  • Create an Account
Close Search
Regulatory Affairs Professionals Society (RAPS)
  • menu_open
    Menu
  • TOPIC
  • search
    Open/Close Search
  • question_answer
    Community
  • school
    Learning Portal
  • calendar_today
    Calendar
  • Storefront
  • shopping_bag
    Marketplace
  • My RAPS perm_contact_calendar
    Open/Close Sign In
  • Join
  • News
  • Membership
  • Education
  • Certification
  • Resources
News
    Regulatory Focus
    About RF
    RF Quarterly
    Subscribe
    Editorial Advisory Committee
    Submission & Guidelines
    Copyright & Terms
    Advertise
      Membership
        Join
        Renew
        Enterprise
        Directory
        Chapters & Local Networks
        Fellows
        Get Involved
        Regulatory Exchange (RegEx)
        • Member Knowledge Center

          Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.

          Get Started
        Education
          Events
          Books
          Courses
          Learning Portal
          Corporate Training
          Convergence
          Euro Convergence
          Executive Development
          • Just released! Fundamentals of Medical Device Regulations, Fifth Edition

            The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.

            Buy the book
          Certification
            My RAC
            Apply
            Prep Tools
            Recertify
            Exam Sites & Scheduling
            About the RAC
            RAC Holders
            RAC Spotlights
            • RAC Spotlights

              Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.

              LEARN MORE
            Resources
              Regipedia
              Suppliers Guide
              About the Profession
              Careers
              Competency Framework
              Code of Ethics
              Scope of Practice
              Workforce Report
                 
                Regulatory Focus™ > News Articles

                Narrow Results

                Today
                Today
                  • 1
                  • 2
                  • 3
                  • 4
                  • 5
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Government Shutdown Looms First PARP Inhibitor Approved in Japan (19 January 2018)

                  • 19 January 2018
                  • By Zachary Brennan 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Showdown Looms as Senate Democrats Prepare to Reject Spending Bill ( WSJ -$) ( Politico ) House passes stopgap bill that would delay medical device tax; Senate Dems vow filibuster ( MassDevice ) ( MedPage Today ) ( Stat ) No One’s Interests Would Be Served by a Shutdown ( Alliance for a Stronger FDA ) The FDA Budget FY 18: Where Does the Money Come From?...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Kite Teams Up With Pfizer on Lymphoma Combo Fed Up With Drugmakers, Hospitals Start Their Own (18 January 2018)

                  • 18 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US US Doctors Plan to Treat Cancer Patients Using CRISPR ( MIT Technology Review ) Gilead's Kite Teams up With Pfizer on a Lymphoma Combo ( Endpoints ) ( Press ) Fed Up With Drug Companies, Hospitals Decide to Start Their Own ( NYTimes ) ( STAT ) How a government shutdown could affect drug safety, flu response, and more ( STAT ) Senate committee advances Azar nom...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Celgene in Talks to Buy Juno Chinese Investors Eye J&J's Diabetes Business (17 January 2018)

                  • 17 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Celgene in discussions to buy Juno Therapeutics ( Financial Times ) ( CNBC ) FDA and Pentagon Forge Breakthrough Designation Agreement ( Focus ) ( Reuters ) ( FDA ) FDA expects IV fluid shortage to improve in coming weeks, months ( Reuters ) ( FDA ) Is Juno worth a $10B-$12B buyout price? Analysts see megabucks deal in the making on reported Celgene talks ( End...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Merck's Keytruda Combo Extends Survival in Lung Cancer Trial Sandoz Files Humira Biosimilar for US Approval (16 January 2018)

                  • 16 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Room for another: Sandoz files Humira biosimilar in US ( BioPharmaReporter ) ( PMLive ) ( Press ) Eiger to abandon blood pressure drug after trial failure ( Reuters ) ( Endpoints ) ( Press ) Big Pharma efforts on Alzheimer's tested by Pfizer exit ( Financial Times ) Transparency: FDA to Release Portions of Redacted Clinical Study Reports ( Focus ) ( STAT ) Op ...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Google Backs UK Universal Vaccine Company Shire Wins EU Approval for Long Acting Hemophilia A Treatment (15 January 2018)

                  • 15 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Gene Therapy Could Make Cancer Care More Unequal, and This Map Shows Why ( MIT Technology Review ) States require doctors to use prescription drug monitoring systems for patients ( Washington Post ) FDA Delays Implementing Parts of 'Intended Use' Rule ( Focus ) ( STAT ) ( Pink Sheet -$) ( Law360 -$) Billionaire-owned Hearing Aid Manufacturer's Former Executives...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: FDA Approves AZ's Lynparza to Treat Breast Cancer with BRCA Mutation Roche's MS Drug Ocrevus Wins EU Approval (12 January 2018)

                  • 12 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer ( Endpoints ) ( Reuters ) ( GenomeWeb ) ( FDA ) Trump expects medical exam to go well Friday ( Reuters ) Drugmakers see a pricing blueprint in an $850,000 gene therapy ( Reuters ) Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018 ( Forbes ) Gene therap...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: FDA Panel Votes Against Testosterone Therapies Endo Subpoenaed for Opioid Information (11 January 2018)

                  • 11 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US The FDA still hates low T drugs — experts bat back a pair of contenders ( Endpoints ) ( Medpage ) ( Fierce ) ( Lipocine ) Endo subpoenaed for information on opioid painkillers ( Reuters ) ( WSJ ) An 'unsustainable' model: Drug makers signal interest in exiting vaccine development during crises ( STAT ) JPM18 Day 3: Valeant and Acorda make plans, promises of M&A...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Bluebird Planning for First Three Approvals by 2019 EU Approves Vertex' Orkambi for Younger Patients (10 January 2018)

                  • 10 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuit ( Reuters ) HHS Secretary Nominee: 'No Silver Bullet' to Bring Down Drug Prices ( Focus ) ( NYTimes ) ( STAT ) ( Fierce ) ( Axios ) Bluebird to seek approvals for three treatments by end of 2019 ( Reuters ) ( Endpoints ) Trial Transparency: NIH Says Final Rule From 2017 has Helped ( Focus ) Face...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Lilly CEO Says Tax Reform May Boost Pharma Deal Making 50 Top Managers Replaced at GSK in Walmsley's 1st Year (9 January 2018)

                  • 09 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Eli Lilly CEO Says Tax Reform May Lead to More Successful Deals ( Bloomberg ) ( CNBC ) Drug Industry Isn't Giving Up on Alzheimer's ( WSJ ) The Winners And Losers Of JP Morgan Monday ( Forbes ) Axovant: That positive p-value we reported yesterday? Um, we screwed that up too ( Endpoints ) Pfizer program seeks closer ties with top universities ( Fierce ) ( Press...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Celgene to Buy Impact Biomedicines for Up to $7B Ablynx Rejects Novo's $3.1B Bid (8 January 2018)

                  • 08 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US $11 billion biotech binge fuels forecasts of 2018 M&A surge ( Reuters ) ( Boston Globe ) Celgene to Buy Impact Biomedicines ( WSJ ) ( STAT ) ( Endpoints ) ( Fierce ) ( Financial Times ) ( Press ) Good morning from JPM ( Politico ) ( STAT ) JPM is like a biotech dating game, just ask these questions before hooking up ( STAT ) Axovant shares blasted as premier ...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: FDA Expands Use of Amgen's Fracture Prevention Drug Xgeva Takeda Signs Alzheimer's Pact With Denali, Strikes Deal to Acquire TiGenix (5 January 2018)

                  • 05 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Drug Industry Is Ripe for a Wave of Deals ( WSJ ) FDA expands use of Amgen's blockbuster drug ( Reuters ) Look out, Teva: Mylan's Copaxone copy has already captured serious share ( Fierce ) Johnson & Johnson pens Alzheimer's gene therapy pact ( Fierce ) ( Endpoints ) Kala Pharma shares damaged by mixed data from PhIII dry eye program ( Endpoints ) ( Press ) C...
                • Story Thumbnail
                  ReconRecon
                  Regulatory NewsRegulatory News

                  Regulatory Recon: Pfizer Signs $830M Discovery Pact with Arvinas Philippines Fines Sanofi, Pulls Dengvaxia Registration (4 January 2018)

                  • 04 January 2018
                  • By Michael Mezher 
                  Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US Pfizer lines up an $830M alliance with Arvinas on protein degradation ( Endpoints ) ( Fierce ) ( Pharmafile ) ( Press ) Drug Policy: The Year In Review, And The Year Ahead ( Health Affairs ) Momenta, Mylan plan trial of biosimilar to Regeneron eye drug ( Reuters ) FDA Denies 3rd Allergan Citizen Petition to Block Restasis Generics ( Focus ) Allergan to cut mo...
                  • 1
                  • 2
                  • 3
                  • 4
                  • 5

                 

                 

                Regulatory Affairs Professionals Society (RAPS)
                5635 Fishers Lane, Suite 400
                Rockville, Maryland 20852

                P +1 301 770 2920 F +1 301 841 7956
                Email: raps@raps.org
                • ABOUT RAPS
                • GOVERNANCE
                • WORK FOR RAPS
                • PRESS ROOM
                • YEAR IN REVIEW
                • CELEBRATE THE PROFESSION
                • The Regulatory Profession
                • RAPS In Europe
                • Privacy Policy
                • TERMS OF USE
                • Advertise
                • FAQ
                • Code of Ethics
                • CALL FOR AUTHORS
                • Contact Us
                • Twitter
                • Facebook
                • LinkedIn
                • Google Plus
                • YouTube
                • InstagramInstagram

                © 2022
                Regulatory Affairs Professionals Society.